TACE combined with tislelizumab and lenvatinib in the treatment of intermediate-to-advanced hepatocellular carcinoma: a retrospective real-world study.

BMC Cancer · 2026 · PMC13137623 · PMID 41862827

Europe PMC DOI

hedged sentence

0.0630

closest p · 1.3× alpha

0.0630

boldest claim

The sentences

borderline significantP = 0.063so close (0.05 < p ≤ 0.1)

The median OS in the group with a pre-treatment tumor diameter < 10.25 cm was 20.3 months (95% CI: 15.331–25.269), while it was 18.2 months (95% CI: 8.204–28.196) in the group with a tumor diameter ≥ 10.25 cm, indicating a borderline significant difference ( P = 0.063).

also in 11,409 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.